However, the long term use of a wild-type FGF1, as a classically known mitogen, may enhance tumorigenic risks and increase the rate of metastasis owing to its strong mitogenic activity, which limits the use of FGF1 in clinic cancer-prone diseases. This evidence concerns the gene FGF1 and cancer.